Lifting malaria's deadly veil: mystery solved in quest for vaccine

August 6, 2012 by Tracy Parish

(Medical Xpress) -- Researchers at the Burnet Institute have made a major breakthrough in the quest for a vaccine against malaria, which causes up to one million deaths each year.

Published in the , this research reveals a key target of the ’s attack against malaria. The findings show that people who are immune to malaria develop antibodies that primarily target a protein known as PfEMP1, which is produced by Plasmodium falciparum, the causative organism of most cases of malaria.

Head of Burnet’s Centre for Immunology and senior author of the study, Professor James Beeson, said that these findings are a major advance towards developing an effective because they unlock the mystery of which malaria proteins, known as variant surface antigens (VSAs), an effective vaccine could target to achieve immunity to malaria.

“The new findings support the idea that a vaccine could be developed that stimulates the immune system so that it specifically mounts a strong response (or attack) against the PfEMP1 protein that malaria produces,” Professor Beeson said.

“A vaccine against malaria is urgently needed to reduce this disease globally and currently there is no licensed malaria vaccine available.”

Co-first author, Jo-Anne Chan said the study also showed that when the immune system attacks other proteins that malaria produces, this is not as effective in protecting people. This emphasises that the immune system has to ‘get it right’ in order to fight malaria infection effectively.

“Our studies of Kenyan children showed that those with antibodies to the PfEMP1 protein had a significantly reduced risk of developing malaria, whereas antibodies to other surface antigens were not associated with protective immunity” she said.

Malaria is caused by a parasite that infects human red and replicates within them. While inside these cells, the malaria parasites produce specific proteins that enable infected cells to stick and clog-up blood vessels in the body. This clogging can occur in organs such as the brain and lungs, and the placenta in pregnant women, and causes severe illness and death.

People who recover from malaria develop antibodies that coat the -infected red blood cells so that they are destroyed by white blood cells (the body’s killer immune cells). The new studies show that the PfEMP1 protein is the major target of these protective antibodies.

Explore further: Improving human immunity to malaria

More information: ‘Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity’. Journal of Clinical Investigation, 2012

Related Stories

Improving human immunity to malaria

August 1, 2012

The deadliest form of malaria is caused the protozoan Plasmodium falciparum. During its life-cycle in human blood, the parasite P. falciparum expresses unique proteins on the surface on infected blood cells.

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.